Prelude Therapeutics (PRLD) Return on Capital Employed (2020 - 2026)

Prelude Therapeutics (PRLD) has 7 years of Return on Capital Employed data on file, last reported at 94.79% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 620.0% year-over-year to 94.79%; the trailing twelve-month figure through Mar 2026 stood at 94.79% (up 620.0% YoY), and the FY2025 full-year result was 99.19%, down 2966.0% from the prior year.
• Return on Capital Employed improved to 94.79% in Q1 2026, from 160.77% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 44.09% in Q1 2022 to a low of 160.77% in Q4 2025.
• A 5-year average of 78.74% and a median of 64.49% in 2023 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed soared 831 bps in 2024 and slumped 7384 bps in 2025, its largest moves.
• Tracing PRLD's Return on Capital Employed over 5 years: stood at 58.91% in 2022, then grew by 9 bps to 53.71% in 2023, then slumped by 62 bps to 86.93% in 2024, then plunged by 85 bps to 160.77% in 2025, then surged by 41 bps to 94.79% in 2026.
• Business Quant data shows PRLD's Return on Capital Employed at 94.79% in Q1 2026, 160.77% in Q4 2025, and 139.7% in Q3 2025.